» Articles » PMID: 24531821

Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-incompatible Transplant Recipients

Overview
Journal Transplantation
Specialty General Surgery
Date 2014 Feb 18
PMID 24531821
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recipients of incompatible allografts are at increased risk of graft loss. We hypothesized that analysis of sequential biopsies from these grafts could define progression of graft lesions and identify features predictive of progression.

Methods: We studied the time course of histologic injury in 745 kidney graft biopsies from 129 patients transplanted with a positive crossmatch human leukocyte antigen-incompatible kidney between 2000 and 2010 (follow-up of 1-9 years).

Results: Graft survival was 98% at 1 year and 80% at 5 years after transplantation. Throughout follow-up, 70% of patients experienced rejection, with 52% showing subclinical rejection in the first year. Cell-mediated rejection was more frequent than antibody-mediated rejection throughout follow-up. Transplant glomerulopathy (TxGN; cg≥1) developed in 47% of patients over the period of the study, as early as 3 months in a few patients. TxGN was preceded by glomerulitis in more than 90% of cases, with a median time interval of 12 months. Glomerulitis and detectable posttransplantation donor-specific antibodies were risk factors for TxGN (P<0.0001 and P<0.05). C4d-negative antibody-mediated rejection manifesting as capillaritis (g≥1 and ptc≥1) with detectable donor-specific antibodies was observed in some recipients (<20%). There was progressively higher average tubulointerstitial scarring (ci+ct) from 3 to 6 to 12 months (P<0.001).

Conclusions: Despite good graft survival, a significant incidence of biopsy-proven rejection occurred in this subset of closely monitored human leukocyte antigen-incompatible recipients throughout follow-up. Microcirculation inflammation, particularly glomerulitis, irrespective of C4d, is associated with a high risk of development of TxGN at 1 year.

Citing Articles

Clinical Impacts of Allograft Biopsy in Renal Transplant Recipients 10 Years or Longer After Transplantation.

Namba-Hamano T, Hamano T, Doi Y, Hiraoka A, Yonishi H, Sakai S Transpl Int. 2024; 37:13022.

PMID: 39091613 PMC: 11292417. DOI: 10.3389/ti.2024.13022.


Preventing Rejection of the Kidney Transplant.

Malhotra D, Jethwani P J Clin Med. 2023; 12(18).

PMID: 37762879 PMC: 10532029. DOI: 10.3390/jcm12185938.


Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots.

Betjes M, De Weerd A Front Med (Lausanne). 2023; 10:1215167.

PMID: 37502354 PMC: 10368955. DOI: 10.3389/fmed.2023.1215167.


Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines.

Couzi L, Malvezzi P, Amrouche L, Anglicheau D, Blancho G, Caillard S Transpl Int. 2023; 36:11244.

PMID: 37448448 PMC: 10336835. DOI: 10.3389/ti.2023.11244.


Transplant Glomerulopathy: Importance of Ultrastructural Examination.

Gibson I Glomerular Dis. 2023; 1(2):68-81.

PMID: 36751426 PMC: 9677739. DOI: 10.1159/000513522.